Side-by-side · Research reference

AdipotidevsGonadorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BFDA-ApprovedHUMAN-REVIEWED7/61 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

Gonadorelin

GnRH Analogue · Diagnostic & Therapeutic

90 minPulsatile interval

73%Ovulation restorationTadesse 2026

2–4 minPlasma half-life

IV / SQ · Pulsatile Pump (Therapeutic) · Single Bolus (Diagnostic)

01Mechanism of Action

Parameter

Adipotide

Gonadorelin

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

GnRH receptors on anterior pituitary gonadotropes

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

GnRH → Pituitary gonadotrope → LH/FSH secretion → Gonadal steroidogenesisSharma 2026

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

Pulsatile LH/FSH release stimulates testicular testosterone or ovarian estradiol/progesterone synthesis; initiates folliculogenesis and spermatogenesisRobin 2026 Sharma 2026

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

Yes — pulsatile delivery preserves negative feedback loops; continuous exposure desensitizes receptors

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to native hypothalamic GnRH

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

Gonadorelin

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

IV preferred (therapeutic) · SQ acceptable (diagnostic)

Frequency

Not specified in available data

—

Evidence basis

Preclinical animal models only

RCT / Expert consensus

Human data

None — no clinical trials reported

—

Diagnostic test (pituitary function)

—

100 mcg IV or SQ bolus

Measure baseline LH/FSH, then 30/60/90 min post-injection. Normal response: LH ≥2× baseline.

Therapeutic (hypothalamic hypogonadism)

—

5–20 mcg IV bolus every 90–120 minutes

Requires portable pulsatile pump. Dose individualized to achieve normal gonadotropin pulsatility.Robin 2026

Pulsatile interval

—

90 minutes (females) · 120 minutes (males)

Mimics physiological GnRH pulse frequency.

Duration

—

Continuous until pregnancy achieved or fertility goals met

3–6 month courses typical for ovulation induction.

Half-life

—

2–4 minutes (plasma)

Necessitates frequent pulsatile administration.

Alternative protocols

—

Exogenous gonadotropins (hCG/hMG) often preferred due to convenience vs pump requirement

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

Gonadorelin

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

Fat loss mechanism

—

None — gonadorelin acts exclusively on reproductive axis

Indirect metabolic effects

—

Restoration of sex hormones may normalize body composition in hypogonadal states

Effect mediated by downstream testosterone/estradiol, not GnRH itself.

04Side Effects & Safety

Parameter

Adipotide

Gonadorelin

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

Injection site reaction

—

Erythema, irritation (pulsatile pump catheter site)

Headache

—

Common with bolus administration

Nausea / abdominal discomfort

—

Transient, dose-related

Ovarian hyperstimulation syndrome (OHSS)

—

Risk with ovulation induction protocols; monitor follicular development via ultrasound

Multiple gestation

—

Increased risk with fertility protocols (twins ~10–15%)

Anaphylaxis

—

Rare hypersensitivity reaction

Pump malfunction / infection

—

Mechanical failure or catheter-site infection with long-term IV pump use

Receptor desensitization

—

Continuous (non-pulsatile) exposure paradoxically suppresses gonadotropinsRobin 2026

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

Gonadorelin

·Pregnancy (except therapeutic infertility protocols)
·Hypersensitivity to gonadorelin or excipients
·Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

Gonadorelin

·Ovarian cysts or PCOS (monitor for OHSS)
·Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)

05Administration Protocol

Parameter

Adipotide

Gonadorelin

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Administer 100 mcg IV or SQ bolus. Draw baseline LH/FSH, then at 30, 60, 90 minutes. Normal response: LH ≥2× baseline, FSH modest rise. Blunted response suggests pituitary pathology; exaggerated response may indicate primary hypogonadism.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

Requires programmable infusion pump with IV catheter. Set pulse interval to 90 min (females) or 120 min (males). Bolus dose 5–20 mcg per pulse. Pump worn continuously; catheter site rotated every 48–72 hrs to prevent infection.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Lyophilised gonadorelin reconstituted with sterile saline or provided diluent. Typically 0.8–3.2 mg dissolved in 8 mL for pump reservoir. Solution stable 7–14 days refrigerated.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

For fertility protocols: ultrasound follicular tracking + serial estradiol/LH measurements. Adjust pulse dose to achieve mid-follicular LH 5–10 IU/L. Ovulation confirmed by progesterone rise or ultrasound.

5. Timing

—

Pulsatile therapy initiated at any point in cycle. Diagnostic test performed in morning (higher baseline LH). For ovulation induction, treatment begins early follicular phase.

06Stack Synergy

Adipotide

— no documented stacks

Gonadorelin

+ hCG (Human Chorionic Gonadotropin)

Multi-pathway

View hCG (Human Chorionic Gonadotropin) →

In hypogonadotropic hypogonadism protocols, gonadorelin restores pituitary LH/FSH pulsatility, while exogenous hCG directly stimulates Leydig cells (acting as LH mimetic) to maintain testosterone production. This dual approach ensures both central axis restoration and immediate gonadal steroidogenesis, preventing testicular atrophy during fertility treatment. hCG's longer half-life (24–36 hrs) complements gonadorelin's pulsatile short-acting profile.

Gonadorelin: 5–10 mcg IV every 120 min (pulsatile pump)
hCG: 1500–2000 IU SQ · 2–3× per week
Duration: 12–24 weeks for spermatogenesis induction
Primary benefit: Fertility restoration in hypothalamic hypogonadism with maintained testicular function